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Background: Diabetes imposes a huge social and
economic impact on nations. However, information
on the costs of treating and managing diabetes in
developing countries is limited. The aim of this study
was to estimate healthcare use and expenditure for
diabetes in Bangladesh.
Methods: We conducted a matched case–control
study between January and July 2014 among 591
adults with diagnosed diabetes mellitus (DMs) and 591
age-matched, sex-matched and residence-matched
persons without diabetes mellitus (non-DMs). We
recruited DMs from consecutive patients and non-DMs
from accompanying persons in the Bangladesh
Institute of Health Science (BIHS) hospital in Dhaka,
Bangladesh. We estimated the impact of diabetes on
healthcare use and expenditure by calculating ratios
and differences between DMs and non-DMs for all
expenses related to healthcare use and tested for
statistical difference using Student’s t-tests.
Results: DMs had two times more days of inpatient
treatment, 1.3 times more outpatient visits, and 9.7
times more medications than non-DMs (all p<0.005).
The total annual per capita expenditure on medical care
was 6.1 times higher for DMs than non-DMs (US$635
vs US$104, respectively). Among DMs, 9.8% reported
not taking any antidiabetic medications, 46.4% took
metformin, 38.7% sulfonylurea, 40.8% insulin, 38.7%
any antihypertensive medication, and 14.2% took anti-
lipids over the preceding 3 months.
Conclusions: Diabetes significantly increases
healthcare use and expenditure and is likely to impose
a huge economic burden on the healthcare systems in
Bangladesh. The study highlights the importance of
prevention and optimum management of diabetes in
Bangladesh and other developing countries, to gain a
strong economic incentive through implementing
multisectoral approach and cost-effective prevention
strategies.
INTRODUCTION
In recent years, the burden of diabetes has
increased worldwide with disproportionally
high morbidity and mortality in developing
countries.1 In Southeast Asia, current esti-
mates indicate that 8.2% of the adult popula-
tion, or 72.1 million people, have diabetes,
which is projected to increase to 123 million
by 2035 as a consequence of ongoing rapid
urbanisation, lifestyle changes and increasing
life expectancy.2 About half of the people
with diabetes remain undiagnosed in this
region, and a further 24.3 million people
have pre-diabetes that will increase to 38.8
million by 2035.2
Bangladesh has a total population of more
than 160 million and is among the countries
with the highest number of people with dia-
betes worldwide.3 The International Diabetes
Federation (IDF) estimated 7.1 million
people with diabetes in Bangladesh and
almost an equal number with undetected
diabetes. This number is estimated to double
by 2025.3 In 2014, the Gross National
Income purchasing power parity (PPP) in
Bangladesh was US$3330. The total govern-
ment expenditure on health was 3.4% of
Key questions
What is already known about this topic?
▸ Diabetes is a costly condition.
▸ People with diabetes have higher healthcare use
compared with matched persons without
diabetes.
▸ Diabetes has potential impacts on individuals
and society.
What are the new findings?
▸ Healthcare expenditure in persons with diabetes
in Bangladesh is six times higher than in
persons without diabetes.
▸ Prevention and management of diabetes is likely
to be a cost-saving approach for Bangladesh.
▸ Low use of statins is a concern.
Recommendations for policy
▸ More focus is needed for secondary prevention
of complications.
▸ Proper management of diabetes and its risk
factors is essential.
▸ There is a need to identify cost-effective strat-
egies for prevention and management of
diabetes.
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total gross domestic product (GDP) in 2008 and per
capita total expenditure on health was only US$15.4
Diabetes care is mostly provided by the Diabetes
Association of Bangladesh (DAB), which is a
not-for-proﬁt association of several hospitals and health
centres across the country. The increasingly high inci-
dence of diabetes is expected to have devastating social
and economic impacts on the overburdened healthcare
systems of the country.
Diabetes is a costly condition and can lead to several
disabling and life-threatening complications, including
stroke, heart attack, chronic kidney diseases, neuropathy,
visual impairment and amputations. Studies in
Bangladesh reported eye problems, chronic kidney dis-
eases, cardiovascular diseases and depression as major
complications.5–8 Although most of these complications
can largely be prevented through the use of several inex-
pensive, easy-to-use and cost-effective interventions, their
use in developing countries, where the majority of
persons with diabetes live, remains tragically low.9 It is
estimated that healthcare expenditure for diabetes
accounts for 10.8% of the total annual healthcare
expenditure worldwide, which totalled at least US$548
billion in 2013 and is projected to exceed US$627
billion by 2035.2 The estimated healthcare cost of dia-
betes was on average US$5621 per person in developed
countries, compared with US$356 in developing coun-
tries.2 A recent study by World Bank found $160 per
year in household expenses for diabetes care (2013
dollars) in Bangladesh.
Economic information on a disease can support the
process of planning and resource allocation allowing
cost-effective and efﬁcient health spending. The social
and economic impact of diabetes is complex and difﬁcult
to measure. Different methods and economic models
have been used to measure the economic burden of
chronic diseases, such as diabetes, but debates about the
most appropriate methods are still ongoing.10 However,
information on the healthcare use, costs, and social and
economic impact of diabetes in developing countries is
generally not available. In this context, we aimed to
conduct for the ﬁrst time a comprehensive matched
case–control study on the economic impact of diabetes
in Bangladesh. The primary objective was to estimate the
total annual per-person expenditure for medical care
among persons with and without diabetes in Bangladesh.
MATERIALS AND METHODS
Study population and location
We conducted a matched, case–control study including
591 persons with diagnosed diabetes mellitus (DMs) and
591 age-matched, sex-matched and residence-matched
controls without diabetes mellitus (non-DMs) at the out-
patient department (OPD) of the Bangladesh Institute
of Health Science (BIHS) hospital between January and
July 2014. A detailed methodology of the study design
has been published elsewhere.11 12 In short, BIHS is a
500-bed multidisciplinary hospital with one of the
largest diabetes OPD visits by patients in a year in
Bangladesh. BIHS is recognised as a national level ter-
tiary healthcare and research institution for diabetes,
and is afﬁliated with the DAB, which has a network of
diabetes centres throughout the country. The BIHS hos-
pital serves a population of about 2.2 million in Dhaka
city and nearby districts.13
Sample size and selection
We considered a sample size of 500 cases and 500 con-
trols to provide 90% power to detect a 5% difference in
rates and proportions between cases and controls.
Inclusion criteria for cases were: adults diagnosed with
diabetes at BIHS OPD according to the WHO criteria,
provision of anthropometric measurements, and written
informed consent. Controls were individuals without a
self-reported history of diabetes matched on a 1:1 basis
to cases by area of residence, age (within a 5-year band)
and sex (male or female). We included all consecutive
patients meeting the inclusion criteria waiting for con-
sultation at the BIHS OPD. Controls were recruited
within 48 hours of recruiting the index case, from either
visitors of patients attending the OPD, or non-blood
related visitors of index diabetes cases, in the same hos-
pitals or the same geographical residence of cases. All
controls underwent identical study questioning and
examination as cases. One completed control interview
was obtained for each case interview.
Data collection
Data were collected by a team consisting of a study phys-
ician, a research ofﬁcer and three research assistants
experienced in hospital data collection. The team was
trained for 4 weeks on diabetes epidemiology, study
protocol, interview skills, research ethics, physical mea-
surements and blood pressure (BP) measurements. Data
were collected through face-to-face interviews using
structured questionnaires and by review of patients’
medical records. The research tools and instruments
used in this study were developed by the IDF Health
Economic Group and translated into Bengali according
to the WHO process of translation, back-translation and
adaptation of research instruments.14 The question-
naires were ﬁeld tested in a similar setting at the OPD of
Bangladesh Institute of Research on Diabetes,
Endocrine and Metabolism (BIRDEM) hospital before
conducting the interviews among 25 cases and 25
control subjects. Feedback from the ﬁeld tests was used
to improve the language and the contents of the ques-
tionnaire and tools, as well as to adapt them to local cir-
cumstances based on previous validated survey items.4
The interview included questions about: socio-
economic status, quality of life, self-satisfaction with
health, self-reported diseases, healthcare use, direct and
indirect costs, tobacco use, impact of health problems,
sources of funds, mental health, physical measurements,
BP and medication use. Physical measurements of
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weight, height, waist circumference and hip circumfer-
ence were conducted according to standard medical
protocols. BP was measured using a digital BP monitor
(Omron, SEM-1, Omron Corporation, Japan). Two
repeated measurements were recorded within an inter-
val of 5 min, alternating the right and left arms. The
average of the two readings was considered.
Hypertension was deﬁned as systolic BP>140 mm Hg
and/or diastolic BP>90 mm Hg.
The estimation of expenditures for medical care
relied on participant recall to ascertain charges for med-
icines, supplies and use of any medical care services. To
increase accuracy of recall, we asked about events occur-
ring only during the previous 90 days. We further
attempted to improve the temporal accuracy by asking
respondents to name and associate a well-remembered
event that had occurred ∼90 days prior to the interview
date. To estimate expenditures for medicines, we asked
participants to show us all medicines they were currently
taking and the most recent prescription and medical
records they received from their doctors, so that we
could record all prescription medicines taken by the par-
ticipant. We then calculated the unit price of each medi-
cine using the Bangladesh online medicine price index
database and costs for medicines per day for each par-
ticipant and multiplied by 365 to get the annual costs
for medicines. For overnight admissions to hospital
(inpatient visits) and visits to OPDs, respondents were
asked to recall the amount of total payment, including
payment for medicines and tests or only a portion of the
total bill or charge. This subset of information from a
single visit was used to estimate the characteristics of all
events of the same kind, including mean length of
inpatient admission and mean payments per admission,
per OPD visits and per purchase of medicine in case of
inpatient visits. The total annual point-of-care service
payment per capita was calculated as the sum of total
annual payment per patient for inpatient care, OPD
care, testing for glucose strips and medicines.
Ethics
The objectives and importance of the research were
explained to all participants before recruitment.
Participation was voluntary and written informed consent
was obtained from all participants. All data sets containing
information on the participants were locked and the iden-
tity of individual participants was kept conﬁdential. The
study was approved by the Research Review Committee
and Ethical Review Committee of the International
Center for Diarrheal Diseases Research, Bangladesh
(PR-13062) and obtained ethical clearance waiver from
Ludwig-Maximilians-Universität (LMU) and BIHS.
Data entry, verification and analysis
All data forms and questionnaires were checked for
errors and necessary corrections were made before data
entry. Data were entered electronically using Microsoft
Access followed by a wide range of consistency checks.
The reliability of the data entry program was veriﬁed by
randomly comparing the data with hard-copy records by
study investigators. Prior to analysis, data were checked
by a statistician for range, consistency and normality.
Suspected values were all rechecked against the hard-
copy records by the study team and excluded from the
analysis data set if a correct response could not be
found. Prior to substantive data analysis, we reduced two
extreme outlier values to the level of the next largest ori-
ginal value. We checked the hospital data and consid-
ered the extreme values to be most probably erroneous
and therefore unreliable. Also, prior to analysis, to
prevent bias arising from rare and uncharacteristically
long hospital stays, we winsorized the hospitalisation
data by reducing two extreme outlier values to the level
of the next largest unmodiﬁed value in the data set
which has previously been used in similar studies.15 16
Descriptive analysis was performed for all variables and
unadjusted comparisons between cases and controls
were performed using Student’s t-tests (for continuous
variables) or χ2 tests (for discrete variables). We esti-
mated the impact of diabetes on healthcare use by calcu-
lating ratios and differences between DMs and non-DMs
and tested for statistical difference using Student’s t-tests.
All statistical analyses were performed using SPSS V.20
(IBM Corporation, USA).
RESULTS
A total of 1265 participants were approached, and 1240
(98%) agreed to participate. Altogether, 40 patients
were excluded—including 15 controls who had a history
of diabetes—8 patients were pregnant and 17 patients
had no medical records available at the time of data col-
lection. Data were collected from 1200 participants.
During analysis, 18 participants were excluded due to
matching problems and incomplete information for a
total of 1182 participants included in the ﬁnal analysis
(ﬁgure 1). The overall mean±SD age of the 1182 partici-
pants was 50.4±11.4 years (table 1). DMs were, on
average, 2 years older than non-DMs (p=0.004), less
likely to be married (80.5% vs 87.5%, p=0.001), less
likely to have completed higher education (year 12 and
above) (30.8% vs 40.8%, p=0.001) and less likely to be
engaged in an occupation as service or business (28.8%
vs 42.0%, p=0.001). Although the cases and controls
were not directly matched on family income, we
observed similar self-reported annual family incomes
per capita, averaging US$1256.4±1307.7 for DMs and US
$1326.9±1971.8 for non-DMs (US$1=78 Bangladesh Taka
(BDT), 2015 Bangladesh Bank).
Use of inpatient care
As shown in table 2, 14.2% of DMs reported at least one
hospital inpatient admission during the past year, com-
pared with 6.6% of non-DMs, which was statistically signiﬁ-
cant (p=<0.001) with a ratio of 2.2. The mean number of
admissions during the past 1 year among participants
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admitted was 1.4 days for DMs and 1.6 days for non-DMs,
which was statistically not signiﬁcant (p=0.388).
The mean length of stay for the most recent hospital
admission among participants admitted was almost the
same length for DMs and non-DMs (4.9 vs 4.8 days,
p=0.878). For all DMs in the sample, the mean annual
inpatient days were 0.9 days, which was calculated as the
product of mean length of stay and estimated annual
admissions per person with diabetes, divided by the total
number of DMs in the sample. For non-DMs, the corre-
sponding ﬁgure was 0.5 days per person per year. The
ratios for annual inpatient days per person, for DMs and
non-DMs, were 2.0. The mean annual inpatient admis-
sions per person for all participants were double for
DMs than non-DMs (0.2 vs 0.1 days) and statistically sig-
niﬁcant (p=0.008).
Use of outpatient care
Table 2 shows the self-reported use of outpatient services
by the study participants. DMs had more than four times
the mean annual visits to OPD compared with non-DMs.
Almost all OPD visits by DMs were to hospital-based
OPD clinics: 4.1 of the 6.2 visits. For non-DMs, the most
visits were to specialists/surgeons: 1.0 of the 4.6 visits.
Both DMs and non-DMs reported <1% mean annual
visits to MBBS doctors, traditional healers, pharmacy
counters, and community health workers.
Use of medicines
Table 2 describes the use of medicines by DMs and
non-DMs. Almost all (97.8%) DMs reported taking at
least one medicine at the time they were interviewed,
compared with one-ﬁfth (20.6%) of non-DMs, which was
highly statistically signiﬁcant (p<0.001). The mean
number of medicines among persons taking any medi-
cine was also signiﬁcantly different between DMs (3.7
medicines) and non-DMs (1.8 medicines, p<0.001). Use
of medicines increased with age and with the length of
time since diagnosis of DM (both p<0.001). The mean
number of medicines taken per person among all parti-
cipants was also statistically signiﬁcant among DMs and
non-DMs (p<0.001) and increased steadily with age and
duration of diabetes.
Payment for services
As shown in table 3, DMs reported paying 6.1 times as
much for total annual medical care services during the
preceding year as non-DMs (US$635 vs US$104). For
DMs, payments were much higher for inpatient services
than outpatient services compared with non-DMs.
However, DMs paid 2.1 times more than non-DMs for
hospital services, in part because payments per admission
were about 1.5 times as high for DMs as for non-DMs. In
the case of payments for OPDs, the ratio of payments for
DMs to payments by non-DMs was less than for inpatient
care but still substantial (2.1, 1.5). Annual total payments
for medicines was 35 385 BDT (US$454) per person for
DMs and 1609 BDT (US$21) for non-DMs. DMs ended
up paying almost 22 times more annually for medicines
than non-DMs, which was highly statistically signiﬁcant
(p<0.001). Total annual payment per person for medi-
cines was the largest cost for DMs, and for non-DMs it
was the annual payment for OPDs.
Use of essential medicines
Table 4 summarises the current use of medicines by
DMs by age range and length of time since diagnosis.
Among DMs, 9.8% reported not taking any anti-diabetic
Figure 1 Flow chart.
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medicine at the time of interview. The most commonly
used anti-diabetic medicine was metformin (46.9%), fol-
lowed by insulin (40.8%) and sulfonylurea (38.7%).
Only 38.7%% of participants with diabetes used any
anti-hypertensive medication. β-Blockers were the most
common (25.9%) anti-hypertensives used. Only 14.2%
of participants with diabetes used any statins, and 7.6%
reported use of any anticoagulants. Almost one-ﬁfth
(20.5%) of DMs were taking vitamins and more than
half (57%) used other medications.
DISCUSSION
This study highlights the large economic burden of dia-
betes on individuals and healthcare systems in
Bangladesh. To the best of our knowledge, this is the
ﬁrst-ever published matched case–control study of
healthcare use and expenditure for diabetes in South
Asia. Our results show that the use of healthcare services
and medicines was dramatically higher among DMs than
among matched non-DMs. DMs reported twice as many
inpatient admissions and annual inpatient treatment
days, 1.3 times more annual outpatient visits and 9.7
times more prescription medicines compared with
non-DMs. Using the IDF estimates of 8.4 million DMs in
Bangladesh, the total estimated healthcare expenditure
for diabetes in Bangladesh is around US$5.3 billion. We
estimated that healthcare expenditure, based on total
annual point-of-service payments, was 6.12 times higher
Table 1 Characteristics of study participants
Variables DMs n (%) Non-DMs n (%) Total n (%) p Value
Age, years
(Mean±SD) 51.4±11.6 49.5±11.1 50.4±11.4 0.004
<40 96 (16.2) 115 (19.5) 211 (17.9) 0.031
40–49 144 (24.4) 145 (24.5) 289 (24.5)
50–59 193 (32.7) 214 (36.2) 407 (34.4)
≥60 158 (26.7) 117 (19.8) 275 (23.3)
Sex
Male 255 (43.1) 255 (43.1) 510 (43.1) 1.000
Female 336 (56.9) 336 (56.9) 672 (56.9)
Marital status
Married 476 (80.5) 517 (87.5) 993 (84.0) 0.001
Single 115 (19.5) 74 (12.5) 189 (16.0)
Education
No education 116 (19.6) 76 (12.9) 192 (16.2) 0.001
Primary 103 (17.4) 96 (16.2) 199 (16.8)
Secondary 190 (32.1) 178 (30.1) 368 (31.1)
Higher secondary and above 182 (30.8) 241 (40.8) 423 (35.8)
Occupation
Unemployed 6 (1.0) 9 (1.5) 15 (1.3) 0.001
Service or business 170 (28.8) 248 (42.0) 418 (35.4)
Housewife 309 (52.3) 271 (45.9) 580 (49.1)
Others 106 (17.9) 63 (10.7) 169 (14.3)
Family size
Median (Q1, Q3) 5 (4, 6) 4 (3, 5) 4 (3, 6) 0.051
Income
Mean annual family income per person (000 BDT) 98.0±102.0 103.5±153.8 100.8±131 0.496
Median monthly family income (Q1, Q3) 000 BDT 25 (15, 42) 25 (16, 40) 25 (15, 40) 0.741
≤30 000 BDT 338 (63.7) 353 (63.8) 691 (63.7) 0.951
>30 000 BDT 193 (36.3) 200 (36.2) 393 (36.3)
Diabetes duration, years
Median (Q1, Q3) 6 (3, 11) NA 6 (3, 11) NA
<5 248 (42.0) NA 248 (42.0) NA
5–10 194 (32.8) NA 194 (32.8)
>10 149 (25.2) NA 149 (25.2)
DMs, patients with diagnosed diabetes mellitus; NA, not applicable; Non-DMs, patients without diabetes mellitus; Q1, quartile 1.
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among DMs than among non-DMs. The impact of the
diabetes study in China, which used similar methods to
our study, showed that point-of-service payments were
4.0 times higher among DMs than among non-DMs.9 A
study in India reported an annual mean direct cost for
diabetes of US$380, which was less than that reported by
our study.17 The results of our study show a much higher
expenditure ratio in Bangladesh compared with China
and other developed countries where the ratio of
expenditure for diabetes ranged from 2.0 to 2.5.18–20
Table 2 Use of inpatient and outpatient services, and medicines by the study participants
DMs Non-DMs Ratio
Mean difference
(95% CI) p Values
Use of inpatient services
Estimated percentage of participants with ≥1 inpatient admission
(last 1 year)
14.2 6.6 2.2 7.6 (4.2 to 11.1) <0.001
Mean number of admissions, last 1 year, among participants
admitted
1.4 1.6 0.9 −0.2 (−0.8 to 0.3) 0.388
Mean length of stay in days, most recent hospital admission,
among participants admitted
4.9 4.8 1.0 0.1 (−1.7 to 2.0) 0.878
Mean annual inpatient days per person, all participants 0.9 0.5 2.0 0.5 (−0.0 to 0.9) 0.053
Mean annual inpatient admissions per person, all participants 0.2 0.1 2.0 0.1 (0.0 to 0.2) 0.008
Use of outpatient services
Estimated percentage of participants with ≥1 outpatient visit
(last 90 days)
59.2 13.7 4.3 45.5 (35.5 to 55.5) 0.271
Mean outpatient visits per participant with ≥1 outpatient visit,
preceding 90 days
1.7 1.5 1.1 0.20 (−0.0 to 0.4) 0.108
Mean annual visits to hospital outpatient departments, per
person, all participants
4.1 0.8 4.9 3.3 (2.8 to 3.7) <0.001
Mean annual visits to a specialist/surgeon, per person, all
participants
0.7 1.0 0.7 −0.3 (−0.7 to −0.0) 0.040
Mean annual visits to an MBBS doctor, per person, all
participants
0.2 0.6 0.4 −0.4 (−0.6 to −0.2) 0.001
Mean annual visits to a traditional healer/quack provider, per
person, all participants
0.6 0.8 0.7 −0.2 (−0.6 to 0.2) 0.253
Mean annual visits to a pharmacy counter, per person, all
participants
0.6 0.8 0.7 −0.2 (−0.6 to 0.2) 0.273
Mean total annual outpatient visits to any medical provider, per
person, all participants
6.2 4.6 1.3 1.5 (0.4 to 2.6) 0.007
Use of medicines
Estimated percentage of persons taking ≥1 medication 97.8 20.6 4.8 77.1 (73.7 to 80.6) <0.001
Mean number of medicines taken among participants taking any
medicines
3.7 1.8 2.1 1.9 (1.7 to 2.1) <0.001
Mean number of medicines taken per person, all participants 3.6 0.4 9.7 3.2 (3.1 to 3.4) <0.001
DMs, patients with diagnosed diabetes mellitus; Non-DMs, patients without diabetes mellitus.
Table 3 Payments for medical care (2014 BDT)
Payments for medical care (2014 BDT) DMs Non-DMs Ratio Mean difference (95% CI) p Values
Mean payment per inpatient admission, if admitted 35 672 24 735 1.4 10 937 (−1914 to 23 787) 0.106
Total annual payment per person for inpatient care 6592 3088 2.1 3504 (−3882 to 10 890) 0.339
Mean payment per outpatient visit 464 316 1.5 148 (−193 to 488) 0.394
Total annual payment per person for outpatient care 5075 3397 1.5 1678 (−1869 to 5226) 0.352
Total annual payment per person for medicines 35 385 1609 22.0 33 776 (29 977 to 37 575) <0.001
Total annual payment per person for glucose testing
strips
2486 NA NA NA NA
Total annual point-of-service payments/charges 49 538 8094 6.1 41 443 (26 710 to 56 176) <0.001
DMs, patients with diagnosed diabetes mellitus; NA, not applicable; Non-DMs, patients without diabetes mellitus.
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Among South Asians, diabetes and its complications
start relatively early with a higher magnitude and severity
compared with Western populations.21 22 A recent study
in Bangladesh showed that relatively newly diagnosed
patients with type 2 diabetes presenting at the OPD of a
hospital had several complications.5 As a result, patients
with diabetes in the clinic are much sicker than their
counterparts in other places and require more medica-
tions and healthcare services. In addition, a greater
number of patients with diabetes presenting at the
clinics in Bangladesh had uncontrolled diabetes, poor
knowledge and were underusing antihypertensives and
statins.5 23 All these factors might have resulted in
expensive, disabling complications and higher use of
medical service as found in our study.
In Bangladesh, as in most developing countries, bar-
riers to public health facilities force the poor to pay for
healthcare out of pocket, often driving them further
into poverty.24 25 As a result, DMs may not seek the
required preventive care, which further increases the
risk of complications and is more costly (if treated at
all). Our participants with diabetes did not use more
inpatient or outpatient services nor take more medicines
than people with diabetes in China.26 27 However, the
controls used very few medicines and services relative to
non-DMs in other countries.15 This underuse of medical
care by the general population is a third driver of the
large diabetes-associated differences that we report.
Medical care in Bangladesh is very costly relative to an
average person’s mean family income, often difﬁcult to
access, and leaves a household vulnerable to the effects
of catastrophic health expenses.24 25 28 Bangladesh has
an opportunity to reduce future medical care costs by
diagnosing diabetes earlier and by using inexpensive
generic medicines much more widely and thus reducing
hospitalisations, disability and mortality.29 30 Our data
suggest that DMs in Bangladesh are less likely to receive
preventive services and medication for proper manage-
ment of diabetes and its complications, and therefore
their high use of inpatient services might be the unfortu-
nate result.
Our study has several limitations that should be kept
in mind when using and interpreting its results. This is
an observational cross-sectional study that estimates the
expenditures and other effects caused by diabetes from
a case–control rather than an experimental comparison.
Data were collected from the consecutive patients with
diabetes and matched controls at the OPD of one large
hospital in Dhaka where people from mostly nearby
regions come for treatment, and thus the results do not
represent Bangladesh as a whole. This type of sampling
might include some bias. However, this hospital is
afﬁliated with the DAB and healthcare costs are similar
to all DAB afﬁliated healthcare centres in Bangladesh.
We excluded undiagnosed cases of diabetes and pre-
diabetes; therefore, the differences and ratios reported
here are probably an overestimate of medical services
usage per person among persons with undiagnosed dia-
betes and pre-diabetes. It is likely that DMs in our
samples were mostly from urban areas, had more
Table 4 Current use of medicines by participants with diabetes
Medicine category Age category (years) p Value DM duration (years) Total p Value
<40 40–49 50–59 ≥60 <5 5–10 >10
Anti-diabetes 87.5 91.7 87.0 94.3 0.097 87.5 87.1 98.7 90.2 <0.001
Metformin 56.2 52.1 46.1 37.3 0.013 49.2 46.9 43.0 46.9 0.483
Sulfonylurea 37.5 35.4 40.9 39.9 0.751 39.5 37.1 39.6 38.7 0.850
Insulin 37.5 42.4 38.9 43.7 0.701 29.8 40.7 59.1 40.8 0.000
Other anti-diabetes 0.0 4.2 3.6 5.7 0.088 2.8 3.6 5.4 3.7 0.429
Anti-hypertensives 13.5 33.3 46.1 50.0 0.000 29.0 43.3 49.0 38.7 <0.001
β-blockers 9.4 20.8 31.1 34.2 0.000 18.1 29.9 33.6 25.9 0.001
Diuretics 0.0 0.0 2.1 1.3 0.257 0.8 1.0 1.3 1.0 0.879
ARB 2.1 4.9 7.3 9.5 0.094 4.4 8.2 7.4 6.4 0.231
CCB 0.0 2.1 1.0 1.3 0.594 1.6 1.0 0.7 1.2 0.799
ACE inhibitors 1.0 5.6 3.1 3.2 0.324 3.2 4.6 2.0 3.4 0.401
Other anti-hypertensives 1.0 7.6 7.3 6.3 0.091 6.0 4.6 8.1 6.1 0.423
Anti-lipids (statins) 3.1 11.8 17.1 19.6 0.000 10.5 17.5 16.1 14.2 0.082
Anti-coagulants 2.1 5.6 9.3 10.8 0.034 4.4 9.3 10.7 7.6 0.041
GIT medicines 7.3 16.7 13.0 13.9 0.211 16.1 13.4 8.1 13.2 0.070
Antibiotics 1.0 0.0 1.0 1.9 0.395 0.8 0.5 2.0 1.0 0.447
Anti-thyroids 2.1 3.5 3.6 6.3 0.416 3.2 4.6 4.7 4.1 0.682
Vitamins 19.8 20.1 17.1 25.3 0.300 18.5 19.1 25.5 20.5 0.211
Other medicines 43.8 66.7 52.8 61.4 0.002 58.9 50.0 63.1 57.0 0.039
ARB, angiotensin receptor blocker; CCB, calcium channel blocker; DM, diabetes mellitus; GIT, gastro intestinal tract.
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complications and were more likely to use and to be
able to afford healthcare services than the general dia-
betes population. A major limitation of this study is
recall bias by cases and controls about different costs
associated with disease and hospitalisation. Some partici-
pants might have failed to differentiate costs for treat-
ment of each individual item mentioned in the
questionnaire, which might affect the results of the
study. In addition, although the case and controls dif-
fered substantially in respect of marital status, education
and occupation, these differences are not relevant to the
analysis and unlikely to change the results presented.
In this study, we minimised under-reporting by limit-
ing counts of both visits and hospitalisations to a 90-day
window and asking about the details of visits and hospi-
talisations for only the most recent encounter within
that period. Since DMs had much more encounters
than controls, any under-reporting in our data should
have the effect of downwardly biasing our estimates of
the effects of diabetes on medical care use. We also per-
formed hospital audits and collected information from
multiple sources to verify the correctness of information
provided, to the extent possible. Regarding medication
use, we asked participants to show us the medicines they
were currently taking and matched with the current pre-
scription. Another limitation is that the presented esti-
mation of the burden does not include the intangible
costs of diabetes, such as pain experienced, human suf-
fering and the reduced quality of life, as well as some of
the non-medical costs attributed to diabetes such as
travel costs, time spent for travel and consultation,
special diets and costs associated with informal care-
givers. A unique strength of this study is its matched
case–control design, which reduced the confounding
bias of age, sex and residence during the recruitment
stage and is the most widely used and accepted
approach for measuring the economic and social
impacts of diabetes.19 20 Despite our matching efforts,
there were some differences between cases and controls,
such as age matching was not perfectly balanced and
this could have introduced bias. However, residence and
sex of the participants were very similar across our cases
and controls, as would be expected, and both groups
were also similar on family income per person and edu-
cational attainment.
The results of our study also suggest, in line with previ-
ous studies from China, that the social and economic
impacts of diabetes might be much higher in developing
countries compared with developed countries, where
diabetes is diagnosed at an early stage and treatment
reaches the target population more effectively.9
Therefore, prevention strategies using low-cost, innova-
tive information technology might be a possible
approach to improve the health systems for diabetes.31–33
The IDF estimated the healthcare costs attributed by dia-
betes in developing countries to be US$356 in 2013,
based on an assumed age–sex adjusted diabetes to non-
diabetes ratio of 2.0 per year per capita.2 If the adjusted
expenditure ratio of 6.1 that we observed had instead
been used, the IDF estimate would have been much
higher. The expenditure ratios reported here imply, as
do analyses using different methods, that in developing
countries the economic burden of diabetes may con-
strain the availability of medical resources for other
health conditions and impede national economic growth
in future years. In Bangladesh, the potential health and
economic impact of diabetes will be particularly large,
because the number of DMs in Bangladesh is growing
rapidly and because of lifestyle changes as a result of
rural to urban migration.34
CONCLUSION
The results of our study indicate that diabetes is likely to
increase healthcare use and expenditure in Bangladesh.
However, larger studies across the country are needed to
better understand its social and economic burden. The
overall healthcare expenditure and health system impact
of diabetes in Bangladesh found by this study is much
higher than previous estimates by international organisa-
tions. The study highlights the importance of prevention
and optimum management of diabetes in Bangladesh,
and other developing countries, in order to gain a
strong economic incentive through implementing
a multisectoral approach and cost-effective prevention
strategies.
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